Australia appears to be experience innovative medication for obesity: Retatrutide. This dual agonist – working on both GLP-1 and GIP receptors – demonstrates remarkable outcomes in international trials, pointing to considerable reductions in weight. While availability hasn't occurred with TGA, many individuals battling being overweight could co